Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of ($0.05), $0.06 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $66.9 million versus the consensus estimate of $75.47 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.